Buch, Englisch, 106 Seiten, Format (B × H): 175 mm x 246 mm, Gewicht: 389 g
Buch, Englisch, 106 Seiten, Format (B × H): 175 mm x 246 mm, Gewicht: 389 g
ISBN: 978-3-11-016848-8
Verlag: De Gruyter
The first to describe the beneficial effects of nitroglycerin in humans was Thomas Lauder Brunton in 1867. At that time, he used nitrate of amyl to treat symptoms of angina. Since then, nitroglycerin and other nitrates have been increasingly used in patients with coronary heart disease and heart failure up to the present day.
During the last 20 years, our knowledge of the function and mechanism of nitroglycerin has grown enormously, since nitric oxide was shown to be the active molecule that provides vasodilation and is produced by the endothelium of the organism itself.
Zielgruppe/Target groups: Physicians
Subjects: Internal Medicine
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Innere Medizin
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Endokrinologie
Weitere Infos & Material
Frontmatter -- Contributors -- Contents -- Introduction -- Role of nitric oxide as a signalling molecule in the cardiovascular system -- From an explosive to the endogenous nitrate: Historical, physiological and clinical aspects -- The role of nitrates in the therapy of congestive heart failure -- Long-term oral treatment with nitrates - what is important? -- Alternatives in long-term nitrate therapy -- The Yin and Yang of nitric oxide, or: the importance of vascular control in acute ischaemia and decrease in cardiac output -- Economic impact of Elantan LA compared to Tenormin and Tildiem LA in the treatment of stable angina in the UK -- Quality of life in angina therapy: focus on the beneficial effects of nitrates -- New trends in interventional cardiology
